Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$46.82 USD

46.82
5,060,914

+0.47 (1.01%)

Updated Nov 4, 2025 04:00 PM ET

After-Market: $46.82 0.00 (0.00%) 5:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.63%
2Buy17.80%
3Hold9.42%
4Sell5.10%
5Strong Sell2.04%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (95 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merck???s Keytruda Gets Priority Review for Bladder Cancer

by Zacks Equity Research

Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.

    Zacks Equity Research

    GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.

      Zacks Equity Research

      Merck Keytruda Gets EU Approval for First-Line Lung Cancer

      by Zacks Equity Research

      Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.

        Zacks Equity Research

        Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

        by Zacks Equity Research

        Value investing is easily one of the most popular ways to find great stocks in any market environment.

          Zacks Equity Research

          Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer

          by Zacks Equity Research

          Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.

            Zacks Equity Research

            Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

            by Zacks Equity Research

            Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

              Zacks Equity Research

              4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017

              by Zacks Equity Research

              Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.

                Zacks Equity Research

                Merck (MRK) Does Well in 2016: Reasons for Outperformance

                by Zacks Equity Research

                Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.

                  Zacks Equity Research

                  Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

                  by Zacks Equity Research

                  Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

                    Zacks Equity Research

                    Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

                    by Zacks Equity Research

                    Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

                      Zacks Equity Research

                      Big Pharma Face Off: Is Merck More Attractive than J&J?

                      by Zacks Equity Research

                      Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks

                        Zacks Equity Research

                        Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

                        by Zacks Equity Research

                        Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

                          Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

                          by Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

                            Tracey Ryniec headshot

                            Is Brexit a Buying Opportunity?

                            by Tracey Ryniec

                            Value investors should keep an eye on what is going on in Great Britain right now.

                              Mark Vickery headshot

                              Q2 Earnings Checklist Keeps Rolling Out: BA, CMCSA, GSK & Others

                              by Mark Vickery

                              After a busy session after the bell yesterday, including strength from Apple, we see another long list of reporting companies this morning.

                                Brian Bolan headshot

                                CDXS and LOGI are Aggressive Growth Stocks

                                by Brian Bolan

                                Biotech supply chain and computer peripherals are the focus

                                  Brian Bolan headshot

                                  Bull of the Day: Codexis (CDXS)

                                  by Brian Bolan

                                  Think of this stock as the supply chain to big biotech and that is driving huge earnings growth.